Creative Medical Technology Holdings, Inc. (CELZ)

NASDAQ: CELZ · IEX Real-Time Price · USD
4.810
0.00 (0.00%)
Apr 19, 2024, 3:11 PM EDT - Market open
0.00%
Market Cap 6.53M
Revenue (ttm) 9,000
Net Income (ttm) -5.29M
Shares Out 1.36M
EPS (ttm) -3.76
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,242
Open 4.810
Previous Close 4.810
Day's Range 4.810 - 4.875
52-Week Range 3.930 - 10.281
Beta 5.04
Analysts n/a
Price Target n/a
Earnings Date May 10, 2024

About CELZ

Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1998
Employees 4
Stock Exchange NASDAQ
Ticker Symbol CELZ
Full Company Profile

Financial Performance

In 2023, CELZ's revenue was $9,000, a decrease of -89.84% compared to the previous year's $88,600. Losses were -$5.29 million, -47.88% less than in 2022.

Financial Statements

News

Creative Medical Technology Holdings Provides Corporate Update

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to imm...

23 days ago - Business Wire

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The com...

6 weeks ago - Business Wire

Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocri...

6 weeks ago - Business Wire

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical tri...

4 months ago - Accesswire

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain

Company reaches next clinical trial milestone for the intramuscular treatment of Chronic Lower Back Pain with the first novel allogenic cellular therapy in the United States PHOENIX , Oct. 10, 2023 /P...

6 months ago - PRNewsWire

Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain

PHOENIX , Sept. 19, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative a...

7 months ago - PRNewsWire

What Is Allogeneic Cell Therapy, And What's Driving This Market's 25%+ Annual Global Growth?

PHOENIX, AZ / ACCESSWIRE / August 24, 2023 / Biotechnology company Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) seems to be witnessing success in the allogeneic cell therapy market. In Q4 ...

8 months ago - Accesswire

The Immunotherapy Market is Expected to Surpass $351.56 Billion by 2030 - Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) is Contributing to this Growth

PHOENIX, AZ / ACCESSWIRE / July 14, 2023 / Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat...

10 months ago - Accesswire

Creative Medical Technology Reports Advancements In Regenerative Medicine And Improvements In Financial Position In Corporate Update

PHOENIX, AZ / ACCESSWIRE / July 13, 2023 / Creative Medical Technology Holdings, Inc. ("Creative Medical Technology") (NASDAQ:CELZ) recently released an update on their drug pipeline and financial sta...

10 months ago - Accesswire

Creative Medical Technology Holdings Regains Compliance With Nasdaq Listing Requirements

PHOENIX, June 28, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative app...

10 months ago - PRNewsWire

Creative Medical Technology Announces $2 Million Share Repurchase Program

PHOENIX , June 12, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative ap...

11 months ago - PRNewsWire

Creative Medical Technology Holdings Announces Reverse Stock Split

PHOENIX , June 9, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative app...

11 months ago - PRNewsWire

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz® Immunotherapy Platform

PHOENIX , May 31, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative app...

11 months ago - PRNewsWire

Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

Advancements May Result in Ability to Treat a Broader Patient Population with Immune Disorders PHOENIX , May 22, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Tech...

11 months ago - PRNewsWire

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Study Demonstrated Significant Efficacy and No Serious Adverse Events PHOENIX , May 18, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company")...

1 year ago - PRNewsWire

Creative Medical Technology Announces Positive Top-Line Results for Type 2 Diabetes Study

PHOENIX, April 12, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading biotechnology company focused on a regener...

1 year ago - PRNewsWire

Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

PHOENIX , April 4, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company" or "We") (NASDAQ: CELZ), a biotechnology company working to revolutio...

1 year ago - PRNewsWire

Creative Medical Technology Files Orphan Drug Designation Application with the U.S. FDA Using the ImmCelz® Platform for the Treatment of Brittle Type 1 Diabetes

PHOENIX, March 23, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-...

1 year ago - PRNewsWire

Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

Independent Studies Validate Enhanced Clinical Grade Cell Production for Patient Use in Multiple Indications at a Fraction of Current Industry Cost PHOENIX , March 21, 2023 /PRNewswire/ -- Creative Me...

1 year ago - PRNewsWire

Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care thr...

1 year ago - Business Wire

Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

Company reaches next clinical trial milestone for treatment of Type 1 Diabetes with the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States PHOENIX , Feb. ...

1 year ago - PRNewsWire

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

AlloStem™ represents the first novel allogenic cellular therapy in the dorsal artery of the pancreas in the United States   PHOENIX , Nov. 3, 2022 /PRNewswire/ -- Creative Medical Technology Holdings,...

1 year ago - PRNewsWire

Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line

PHOENIX , Oct. 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, ...

1 year ago - PRNewsWire

Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study

--Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating Chronic Lower Back Pain -- PHOENIX , Sept. 26, ...

1 year ago - PRNewsWire